Literature DB >> 22644142

A multidisciplinary clinic for individualizing management of patients at increased risk for breast and gynecologic cancer.

Natalie J Engel1, Patricia Gordon, Darcy L Thull, Beth Dudley, Judy Herstine, Rachel C Jankowitz, Kristin K Zorn.   

Abstract

Increasing awareness of the hereditary component of breast and ovarian cancer has driven interest in creating clinics for the patient population at high risk for these cancers. Identifying adequate space and appropriate staff, coordinating multiple providers' schedules, establishing referral criteria, and addressing billing and reimbursement concerns are just some of the issues that are involved in the creation of a multidisciplinary high risk breast and ovarian cancer program. We provide an overview of the clinic structure at the Magee-Womens Hospital High Risk Breast and Ovarian Cancer Program (HRBOCP), which was created in 2002 due to recognition of a need for a more coordinated model of providing care for women at increased risk for breast and ovarian cancer. The goals of the HRBOCP are to evaluate women at high risk for breast and ovarian cancer and to organize their clinical care in a multidisciplinary setting staffed by experts in the field; to provide updates on new data regarding screening recommendations, prevention options, and risk factors pertinent to an individual's cancer risk; to provide ongoing support to patients and to coordinate family communication when appropriate; and to facilitate enrollment in appropriate research studies and registries.

Entities:  

Mesh:

Year:  2012        PMID: 22644142     DOI: 10.1007/s10689-012-9530-x

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  32 in total

1.  Managing patients at high risk for hereditary breast cancer: a guide for the practicing physician.

Authors:  James C Cusack; Kevin S Hughes
Journal:  Ann Surg Oncol       Date:  2012-06       Impact factor: 5.344

2.  The lack, need, and opportunities for decision-making and informational tools to educate primary-care physicians and women about breast cancer chemoprevention.

Authors:  Peter M Ravdin
Journal:  Cancer Prev Res (Phila)       Date:  2010-06

3.  Ten genes for inherited breast cancer.

Authors:  Tom Walsh; Mary-Claire King
Journal:  Cancer Cell       Date:  2007-02       Impact factor: 31.743

4.  The carrier clinic: an evaluation of a novel clinic dedicated to the follow-up of BRCA1 and BRCA2 carriers--implications for oncogenetics practice.

Authors:  E K Bancroft; I Locke; A Ardern-Jones; L D'Mello; K McReynolds; F Lennard; Y Barbachano; J Barwell; L Walker; G Mitchell; H Dorkins; C Cummings; J Paterson; Z Kote-Jarai; A Mitra; S Jhavar; S Thomas; R Houlston; S Shanley; R A Eeles
Journal:  J Med Genet       Date:  2010-05-14       Impact factor: 6.318

Review 5.  Hereditary breast cancer: practical pursuit for clinical translation.

Authors:  Henry T Lynch; Carrie Snyder; Jane Lynch
Journal:  Ann Surg Oncol       Date:  2012-03-21       Impact factor: 5.344

6.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.

Authors:  J P Struewing; P Hartge; S Wacholder; S M Baker; M Berlin; M McAdams; M M Timmerman; L C Brody; M A Tucker
Journal:  N Engl J Med       Date:  1997-05-15       Impact factor: 91.245

7.  Hereditary breast/ovarian and colorectal cancer genetics knowledge in a national sample of US physicians.

Authors:  L Wideroff; S T Vadaparampil; M H Greene; S Taplin; L Olson; A N Freedman
Journal:  J Med Genet       Date:  2005-03-22       Impact factor: 6.318

8.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

Authors:  D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

9.  Developments in Clinical Practice: Follow up Clinic for BRCA Mutation Carriers: a Case Study Highlighting the "Virtual Clinic".

Authors:  Audrey Ardern-Jones; Rosalind Eeles
Journal:  Hered Cancer Clin Pract       Date:  2004-02-15       Impact factor: 2.857

10.  PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene.

Authors:  Nazneen Rahman; Sheila Seal; Deborah Thompson; Patrick Kelly; Anthony Renwick; Anna Elliott; Sarah Reid; Katarina Spanova; Rita Barfoot; Tasnim Chagtai; Hiran Jayatilake; Lesley McGuffog; Sandra Hanks; D Gareth Evans; Diana Eccles; Douglas F Easton; Michael R Stratton
Journal:  Nat Genet       Date:  2006-12-31       Impact factor: 38.330

View more
  6 in total

1.  Involvement and Influence of Healthcare Providers, Family Members, and Other Mutation Carriers in the Cancer Risk Management Decision-Making Process of BRCA1 and BRCA2 Mutation Carriers.

Authors:  Athena Puski; Shelly Hovick; Leigha Senter; Amanda Ewart Toland
Journal:  J Genet Couns       Date:  2018-03-29       Impact factor: 2.537

Review 2.  Hereditary ovarian cancer: not only BRCA 1 and 2 genes.

Authors:  Angela Toss; Chiara Tomasello; Elisabetta Razzaboni; Giannina Contu; Giovanni Grandi; Angelo Cagnacci; Russell J Schilder; Laura Cortesi
Journal:  Biomed Res Int       Date:  2015-05-17       Impact factor: 3.411

3.  General Practitioners and Breast Surgeons in France, Germany, Netherlands and the UK show variable breast cancer risk communication profiles.

Authors:  Claire Julian-Reynier; Anne-Deborah Bouhnik; D Gareth Evans; Hilary Harris; Christi J van Asperen; Aad Tibben; Joerg Schmidtke; Irmgard Nippert
Journal:  BMC Cancer       Date:  2015-04-09       Impact factor: 4.430

Review 4.  Proteomics in cancer biomarkers discovery: challenges and applications.

Authors:  Reem M Sallam
Journal:  Dis Markers       Date:  2015-04-27       Impact factor: 3.434

5.  Hereditary ovarian cancer risk reduction: a retrospective evaluation of patient perspectives and service provision at a regional hereditary gynaecologic cancer clinic 2006-2016.

Authors:  Lauren Adolph; Ashley Warias; Jocelyn Stairs; Kelly Collins-McNeil; Lynette Penney; Katharina Kieser
Journal:  BMC Womens Health       Date:  2022-06-29       Impact factor: 2.742

Review 6.  Ovarian cancer: can proteomics give new insights for therapy and diagnosis?

Authors:  Angela Toss; Elisabetta De Matteis; Elena Rossi; Lara Della Casa; Anna Iannone; Massimo Federico; Laura Cortesi
Journal:  Int J Mol Sci       Date:  2013-04-15       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.